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 Implication for health policy/practice/research/medical edu-
cation:
RNA interference (RNAi), the degradation of cognate mRNA by 
small interfering RNA (siRNA), has emerged as a novel therapeutic 
entity for viral infections. This novel strategy may offer the potential 
to eliminate HCV infection. This article is useful for all researchers 
who concern about new therapeutic approaches for viral hepatitis.
Hepatitis viruses are the leading cause of liver cirrho-
sis and hepatocellular carcinoma (HCC) worldwide. The 
hepatitis C virus (HCV), together with the hepatitis B virus 
(HBV), accounts for 75% of all cases of liver disease around 
the world, with chronic hepatitis, cirrhosis, and HCC 
causing 500,000 to 1.2 million deaths per year (1-3). More 
than 170 million people worldwide have chronic HCV in-
fection. According to the 2002 WHO report, chronic liver 
diseases were responsible for 1.4 million deaths, includ-
ing 796,000 deaths due to cirrhosis and 616,000 deaths 
due to primary liver cancer. At least 20% of these deaths 
(more than 280,000 deaths) are probably attributable to 
HCV infection (4). With the WHO officially recognizing 
hepatitis as a global health issue, more research needs to 
be conducted to develop new therapeutic interventions. 
Current antiviral therapies for chronic viral hepatitis are 
effective only in approximately half of the patients (5). 
The most widely available agents for the treatment of 
chronic hepatitis are interferon-α (IFN-α) and nucleoside 
analogs such as lamivudine or adefovir (6, 7). However, 
treatment with these agents has some disadvantages, 
including possible serious adverse effects in the case of 
interferon treatment or recurrence of viremia after dis-
continuation of therapy and development of resistant 
mutants after prolonged lamivudine treatment (8-11). 
Moreover, nucleoside analogs such as 3TC-lamivudine 
only interfere with viral replication and do not induce 
cessation of the process. The low efficacy of these agents, 
their adverse effects, and development of resistant viral 
mutations are major impediments to the clinical appli-
cation of these agents for the treatment of viral hepati-
tis (6). These shortcomings necessitate the development 
of alternative treatment strategies. Sequence-specific 
gene silencing using RNA interference (RNAi) is a Nobel 
prize–winning technology that represents a promising 
new approach to overcome viral infections (5, 12-14). RNA 
interference is an evolutionary mechanism for protect-
ing the genome against invasion by mobile genetic ele-
ments such as transposons and viruses (6). It is a process 
by which small interfering RNA (siRNA) with specific 
target sequences induce silencing of homologous genes 
by binding to their complementary mRNA and inducing 
the elimination of the mRNA molecule (15). This process 
occurs post-transcriptionally in the cytoplasm and is 
mediated by small RNA molecules (21 to 25 nucleotides 
in length) that bind to their complementary mRNA tar-
gets and silence the expression of these targets (6). The 
phenomenon of RNA interference (RNAi) was first de-
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scribed by Fire et al. They observed that in the nematode 
Caenorhabditis elegans, the presence of double-stranded 
RNA (dsRNA) resulted in sequence-specific gene silenc-
ing at the post-transcriptional level. The RNAi pathway 
has since been recognized as a conserved biological path-
way, and several experimental models have contributed 
to the understanding of this process (15, 16).
Subsequent  to  the  discovery  of  RNAi  pathways  and 
their ability to silence a specific gene sequence, research-
ers have proposed that this natural protection response 
might be used for therapeutic purposes. The ability to 
achieve  potent  knockdown  of  a  gene  of  interest  with 
high sequence specificity makes RNAi a powerful tool 
for treating a variety of diseases. Since RNAi, as a natural 
mechanism of defense, has an antiviral effect in plants 
and mammalian cells, pathogenic human viruses were 
considered a good starting point for evaluating the 
therapeutic  potential  of  RNAi  (17-20).  Recently,  several 
reports have demonstrated the use of RNAi for weaken-
ing of viral infection and replication in cultured cells. For 
instance, several studies have shown its antiviral effects 
against HIV and HBV and HCV (6, 12, 21-25). 
The  in  vivo  efficacy  of  RNAi  against  a  virus  was  first 
demonstrated by McCaffrey et al. In their study, they co-
delivered an HBV replicon and an expression unit encod-
ing an anti-HBV RNAi in mice. Their results showed that a 
significant knockdown (99%) of the HBV core antigen in 
hepatocytes could be achieved by the RNAi mechanism, 
providing an important proof of principle for future anti-
viral applications of RNAi in the liver.(12) In another study 
designed by Amir Shlomai and Yosef Shaul, in order to 
evaluate the anti-HBV therapeutic potential of RNAi, the 
levels of viral proteins and transcripts as well as the viral 
replicative forms were analyzed. The results showed that 
RNAi is an efficient approach for reducing the level of HBV 
transcripts and proteins and for suppressing HBV replica-
tion (26). Many other studies have shown that co-trans-
fection of RNAi molecules targeting specific sequences in 
the HBV or HCV genome results in a significant reduction 
in the corresponding levels of viral transcripts and pro-
teins. This reduction is highly selective, because only the 
homologous transcripts and proteins were eliminated (8, 
13). Thus, RNAi-based therapies have a number of inherent 
and fundamental benefits (8, 27).
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